AnaptysBio Q2FY26 Results: Adj. EPS beats est, sales up 23%
AnaptysBio (ANAB) reported Q2FY26 adjusted EPS of $(0.11), beating estimates by 76%. Revenue rose 23% YoY to $27.5M, exceeding expectations. Net income surged to $177.3M due to a $181.5M tax benefit. Jemperli sales grew 34% YoY to $644M. Cash position declined to $164.1M.
How this was made
The 30-second read
Why it matters
Earnings beat may trigger short-term buying, but investors should assess sustainability of cash flow.
Market read
First earnings release for the quarter; provides new data for valuation models.
What to watch
Litigation costs and royalty decline could pressure future margins.
Background
AnaptysBio separated from First Tracks Biotherapeutics, impacting its tax position and cash balance.
Ticker impact
AnaptysBio reported Q2FY26 adjusted EPS beat and a 23% sales increase, providing fresh earnings data.
Potential modest price rise on earnings beat, but watch for volatility due to tax benefit normalization.
Adjusted EPS beat and revenue growth are positive, but the net income is largely accounting-driven, limiting upside.
Market effects
Biotech earnings may influence peer valuations, especially companies with royalty streams.
Limited to US biotech sector.
Modest, confined to specialty pharma investors.
Counterpoint
Tax benefit is non-recurring; core cash generation remains weak, suggesting caution.
Key entities
- companyAnaptysBio
Biotech firm reporting Q2FY26 results.
- companyGSK
Partner in Jemperli royalties and litigation.
